N/A
N=15
Effects of Glutamine on GLP-1 and Insulin Secretion in Man
Type 2 Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT00673894 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Postprandial Glucose Area Under the Curve (AUC) — 1341; 1463 mmol/L*t
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Sitagliptin (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- Garvan Institute of Medical Research
- Primary completion
- Dec 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postprandial Glucose Area Under the Curve (AUC) |
1341; 1463 | — |
| SECONDARY Fructosamine |
244; 240 | — |
Summary
This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.
Eligibility Criteria
Inclusion Criteria
- Type 2 diabetes, on metformin or diet alone (not sulphonylureas or insulin)
Exclusion Criteria
- Malabsorption, renal or liver disease, treatment with steroids
Data sourced from ClinicalTrials.gov (NCT00673894). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.